B7-330 vendors competing

No vendor pricing available for this peptide yet.

Research details

B7-33 — research data

Half-life~2 hours. Daily dosing in research.
Regulatory statusNot FDA-approved
NCAA D1Not listed

Overview

About B7-33

Mechanism of action

Single-chain analogue of H2 relaxin B-chain; selectively activates RXFP1 receptor; anti-fibrotic via collagen remodeling; vasodilatory; cardioprotective without uterine relaxation effects.

Safety profile

Limited human data. Vasodilation (hypotension); generally well-tolerated in animal studies. · Preclinical compound; no adverse signals in studies; anti-fibrotic potential; early stage

Related pages

More on B7-33

Failed to fetch